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Background: Long-term clinical outcomes following multivessel (≥2 arteries) versus single-vessel percutaneous coronary intervention (PCI) in the 
era of drug-eluting stents (DES), glycoprotein (GP) IIb/IIIa inhibitors, and clopidogrel pretreatment have not been well characterized. We compared 
in-hospital and long-term clinical outcomes in patients who underwent multivessel versus single-vessel non-emergent PCI.
Methods: Using the 2004/2005 Cornell Angioplasty Registry, we evaluated 2,455 consecutive patients undergoing urgent or elective PCI and 
compared in-hospital outcomes, 1-year, and long-term mortality. We excluded patients presenting with an ST-elevation MI ≤24 hours, hemodynamic 
instability/shock, thrombolytic therapy ≤7 days, or renal insufficiency (creatinine ≥4 mg/dL). All-cause mortality was obtained for 100% of patients, 
with a mean follow-up of 4.4 ± 1.1 years.
Results: Of the 2,455 study patients, 367 patients (14.9%) underwent multivessel PCI, and 2,086 (85.1%) underwent single-vessel PCI. DES were 
used in 87% of PCIs, glycoprotein IIb/IIIa inhibitors were used in 53% of patients. The incidence of in-hospital death (0% vs. 0.3%, p=0.600), post-
procedural MI (8.4% vs. 6.5%, p=0.178), and MACE including death, stroke, emergent CABG/PCI, and MI (8.4% vs. 6.8%, p=0.270) was similar in 
multivessel versus single-vessel PCI, respectively. The incidence of 1-year mortality (1.9% vs. 3.4%, p=0.148) and long-term Kaplan-Meier mortality 
(11.7% vs. 11.7%, p=0.903) were also similar in multivessel vs. single-vessel PCI, respectively. After adjustment with a multivariate Cox regression 
analysis, multivessel PCI was not an independent predictor of 1-year (HR 0.79, 95%CI 0.32-1.93, p=0.598) or long-term mortality (HR 1.13, 95%CI 
0.76-1.69, p=0.537).
Conclusions: In contemporary PCI utilizing DES, glycoprotein IIb/IIIa inhibitors and clopidogrel, multivessel PCI is associated with similar rates of 
in-hospital complications and comparable 4-year survival compared to single-vessel PCI. This data suggest that multivessel PCI may be a safe and 
practical revascularization strategy in a selected patient cohort.
